MedTrace Logo

Assessment of Wall Thickness in Hypertrophic Cardiomyopathy

NCT02234336 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2019-02-05

No results posted yet for this study

Summary

Assessment of wall thickness in hypertrophic cardiomyopathy (HCM) is of diagnostic and prognostic importance given its known association with sudden cardiac death. However, data regarding comparison of imaging modalities for this key measurement is lacking. This study seeks to compare assessment of maximum wall thickness between clinically indicated echocardiography (with and without contrast) and clinically indicated cardiac magnetic resonance imaging.

Conditions

Interventions

PROCEDURE

Noncontrast echocardiography

PROCEDURE

Contrast Echocardiography

PROCEDURE

Cardiac magnetic resonance imaging

Sponsors & Collaborators

  • GE Healthcare

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Patricia Pellikka, MD · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2017-07-25
Completion
2017-07-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02234336 on ClinicalTrials.gov